| abstract |
The present invention provides a novel method for treating leukemia in a host that has been previously treated with a BrcAbl tyrosine kinase inhibitor comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with. a C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C5-10 aryl, and and wherein each. Rc is independently selected from the group comprising H, C1-5, alkyl, C1-5 alkenyl, C1-5.alkynyl an hydroxy protecting group |